MX386150B - Tasimelteon para tratar el síndrome de smith-magenis. - Google Patents

Tasimelteon para tratar el síndrome de smith-magenis.

Info

Publication number
MX386150B
MX386150B MX2017002796A MX2017002796A MX386150B MX 386150 B MX386150 B MX 386150B MX 2017002796 A MX2017002796 A MX 2017002796A MX 2017002796 A MX2017002796 A MX 2017002796A MX 386150 B MX386150 B MX 386150B
Authority
MX
Mexico
Prior art keywords
smith
treatment
tasimelteon
magenis syndrome
magenis
Prior art date
Application number
MX2017002796A
Other languages
English (en)
Spanish (es)
Other versions
MX2017002796A (es
Inventor
Christian Lavedan
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX386150(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2017002796A publication Critical patent/MX2017002796A/es
Publication of MX386150B publication Critical patent/MX386150B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Processing Of Solid Wastes (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Led Device Packages (AREA)
  • Saccharide Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Indole Compounds (AREA)
MX2017002796A 2014-09-02 2015-08-29 Tasimelteon para tratar el síndrome de smith-magenis. MX386150B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US201562169635P 2015-06-02 2015-06-02
PCT/US2015/047610 WO2016036619A1 (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Publications (2)

Publication Number Publication Date
MX2017002796A MX2017002796A (es) 2017-06-09
MX386150B true MX386150B (es) 2025-03-18

Family

ID=54147267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002796A MX386150B (es) 2014-09-02 2015-08-29 Tasimelteon para tratar el síndrome de smith-magenis.

Country Status (17)

Country Link
US (5) US10179119B2 (enExample)
EP (2) EP3188727B1 (enExample)
JP (3) JP6903571B2 (enExample)
KR (2) KR20170048541A (enExample)
CN (2) CN106604726A (enExample)
AU (2) AU2015312252B2 (enExample)
BR (1) BR112017003644A2 (enExample)
CA (2) CA3124872A1 (enExample)
DK (1) DK3188727T3 (enExample)
ES (1) ES2936833T3 (enExample)
FI (1) FI3188727T3 (enExample)
HR (1) HRP20230070T1 (enExample)
HU (1) HUE061051T2 (enExample)
MX (1) MX386150B (enExample)
PT (1) PT3188727T (enExample)
SI (1) SI3188727T1 (enExample)
WO (1) WO2016036619A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CN106604726A (zh) * 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
EP3761974A1 (en) * 2018-03-04 2021-01-13 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
JP2022500420A (ja) * 2018-09-12 2022-01-04 バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. 睡眠又は睡眠後パフォーマンスの改善
NZ811397A (en) 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof
US20230314471A1 (en) 2020-08-27 2023-10-05 Yokowo Co., Ltd. Inspection device
AU2022345260A1 (en) * 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
IL330095A (en) * 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Also Published As

Publication number Publication date
JP7252390B2 (ja) 2023-04-04
US20190105297A1 (en) 2019-04-11
EP4137129A1 (en) 2023-02-22
KR20170048541A (ko) 2017-05-08
ES2936833T3 (es) 2023-03-22
EP3188727B1 (en) 2022-11-09
US20170239210A1 (en) 2017-08-24
JP2022078291A (ja) 2022-05-24
SI3188727T1 (sl) 2023-03-31
NZ729901A (en) 2020-09-25
CN116098887A (zh) 2023-05-12
JP6903571B2 (ja) 2021-07-14
AU2020239640A1 (en) 2020-10-15
US20240293355A1 (en) 2024-09-05
JP2017526693A (ja) 2017-09-14
DK3188727T3 (da) 2023-02-06
US20200237712A1 (en) 2020-07-30
CA2957588A1 (en) 2016-03-10
US20220133681A1 (en) 2022-05-05
US10653665B2 (en) 2020-05-19
AU2015312252B2 (en) 2020-07-02
CA3124872A1 (en) 2016-03-10
KR20240015729A (ko) 2024-02-05
WO2016036619A1 (en) 2016-03-10
HUE061051T2 (hu) 2023-05-28
CN106604726A (zh) 2017-04-26
AU2020239640B2 (en) 2020-11-05
JP7132277B2 (ja) 2022-09-06
CA2957588C (en) 2021-08-31
BR112017003644A2 (pt) 2017-11-28
PT3188727T (pt) 2023-01-30
US10179119B2 (en) 2019-01-15
NZ765911A (en) 2023-08-25
FI3188727T3 (fi) 2023-02-20
HRP20230070T1 (hr) 2023-03-17
JP2020143159A (ja) 2020-09-10
US11266622B2 (en) 2022-03-08
MX2017002796A (es) 2017-06-09
AU2015312252A1 (en) 2017-03-30
EP3188727A1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
DK3201148T3 (da) Sammensmeltet telluratglas med forarbejdningstemperaturer på 420ºC
GT201700104A (es) Agonistas parciales del receptor de insulina
DK3888641T3 (da) Anvendelse af cannabidiol i behandling af anfald i forbindelse med doose-syndrom
GEAP201914237A (en) Heteroaryls and uses thereof
DK3212208T3 (da) Anvendelse af l. reuteri til forebyggelse eller behandling af mikrobiotadysbiose tidligt i livet
DK3129563T3 (da) Bærestruktur
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
EA201700142A1 (ru) Полимерная композиция для слоя элемента слоя
DE112015001587A5 (de) Lageranordnung
MX376367B (es) Activacion del factor x.
CY1119212T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης
MX380683B (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.
ES1106111Y (es) Estructura de montaje y ampliacion de mesas
TN2014000468A1 (fr) اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها
TN2014000355A1 (fr) طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية
ES1119305Y (es) Lámpara de mesa
TN2014000377A1 (fr) طائرة كهربائية كاتمة للصوت
DOS2014000289S (es) Mesas
ES1138533Y (es) Dispositivo para evitar el vuelco accidental de recipientes
TN2014000388A1 (fr) منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية لتوليد الطاقة الكهربائية الحرة الايكولوجية المضاعفة